Skip to content

Multidimensional Evaluation Method and Application for Assessing Protective Capacity Against Infectious Diseases with Fingerstick Blood on a Highly Sensitive Microsample Analysis Platform

Multidimensional Evaluation Method and Application for Assessing Protective Capacity Against Infectious Diseases with Fingerstick Blood on a Highly Sensitive Microsample Analysis Platform

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088949
Enrollment
Unknown
Registered
2024-08-29
Start date
2024-10-17
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosi

Interventions

Gold Standard:To achieve accurate detection and diagnosis, we will utilize gold standard methods specific to each type of infectious disease. Additionally, we will integrate other clinical symptoms an
Index test:?-interferon gamma release assay (IGRA),Enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CL assay), polymerase chain reaction (PCR), second-generation sequencing (NG

Sponsors

Shenzhen Bao'an People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Controls (HC): Individuals with no history of severe illness and who are deemed healthy following a medical examination. 2. Infected Patients (Patient): Individuals currently suffering from a prevalent infectious disease or those who have recovered from such a condition.

Exclusion criteria

Exclusion criteria: 1. Presence of significant diseases such as cancer; 2. Severe mental disorders that hinder the ability to fully cooperate with and complete all tests; 3. Immunosuppression, including long-term use of steroids and immunosuppressive drugs, undergoing organ transplantation, or concurrent HIV infection, leading to negative T-cell immune responses.

Design outcomes

Primary

MeasureTime frame
IFN-gamma concentration;Antibody Levels;

Secondary

MeasureTime frame
Symbol of disease;

Countries

China

Contacts

Public ContactYuzhong Xu

Shenzhen Bao'an People's Hospital

254501651@qq.com+86 134 1847 3391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026